2D proliferation assays showed that in the absence of EGFR inhibition, lack of activation of the ERK1/2 pathway led to a strong decrease in cell growth while impairment of the AKT pathway reduced cell numbers less efficiently, except in ErbB2 tumor cells. The gene discussed is ERBB2; the disease is neoplasm.